These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7974392)

  • 1. Binding of low molecular weight heparin (Tinzaparin sodium) to bovine endothelial cells in vitro.
    Larnkjaer A; Ostergaard PB; Flodgaard HJ
    Thromb Res; 1994 Jul; 75(2):185-94. PubMed ID: 7974392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding, internalization and degradation of heparin and heparin fragments by cultured endothelial cells.
    Vannucchi S; Pasquali F; Porciatti F; Chiarugi V; Magnelli L; Bianchini P
    Thromb Res; 1988 Feb; 49(4):373-83. PubMed ID: 2837834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding and endocytosis of heparin by human endothelial cells in culture.
    Bârzu T; Molho P; Tobelem G; Petitou M; Caen J
    Biochim Biophys Acta; 1985 May; 845(2):196-203. PubMed ID: 3995089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affinity of binding of radiolabeled (125I) heparin and low molecular weight heparin fraction CY 222 to endothelium in culture.
    Psuja P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(3):429-36. PubMed ID: 2444518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of tinzaparin: a heparinase-digested low-molecular-weight heparin.
    Hedner U
    Semin Thromb Hemost; 2000; 26 Suppl 1():23-9. PubMed ID: 11011803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans.
    Iversen N; Sandset PM; Abildgaard U; Torjesen PA
    Thromb Res; 1996 Nov; 84(4):267-78. PubMed ID: 8948051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of heparin to human microvascular endothelial cells and the effect on proliferation.
    Bikfalvi A; Dupuy E; Ruan C; Tobelem G; Leseche G; Caen J
    Cell Biol Int Rep; 1988 Nov; 12(11):931-42. PubMed ID: 3228862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy.
    Mousa SA; Mohamed S
    Oncol Rep; 2004 Oct; 12(4):683-8. PubMed ID: 15375485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs.
    Brindley CJ; Taylor T; Diness V; Oestergaard PB; Chasseaud LF
    Xenobiotica; 1993 Jun; 23(6):575-88. PubMed ID: 8212732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
    Amirkhosravi A; Mousa SA; Amaya M; Francis JL
    J Thromb Haemost; 2003 Sep; 1(9):1972-6. PubMed ID: 12941039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The binding of unfractionated heparin and low molecular weight heparin to thrombin-activated human endothelial cells.
    Young E; Venner T; Ribau J; Shaughnessy S; Hirsh J; Podor TJ
    Thromb Res; 1999 Dec; 96(5):373-81. PubMed ID: 10605952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of heparin to human endothelial cell monolayer and extracellular matrix in culture.
    Psuja P; Drouet L; Zawilska K
    Thromb Res; 1987 Aug; 47(4):469-78. PubMed ID: 3310327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of low-molecular-weight heparin to aortic endothelium in rabbits.
    Gensini GF; Fortini A; Lombardi A; Pesciullesi E; Pieroni C; Neri Serneri GG
    Haemostasis; 1984; 14(6):466-72. PubMed ID: 6534819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells.
    Nader HB; Pinhal MA; Baú EC; Castro RA; Medeiros GF; Chavante SF; Leite EL; Trindade ES; Shinjo SK; Rocha HA; Tersariol IL; Mendes A; Dietrich CP
    Braz J Med Biol Res; 2001 Jun; 34(6):699-709. PubMed ID: 11378657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The internalization and release of heparins by cultured endothelial cells: the process is cell source, heparin source, time and concentration dependent.
    Hiebert LM; McDuffie NM
    Artery; 1990; 17(2):107-18. PubMed ID: 2155600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: role of the low affinity heparin-like bFGF receptors.
    Rusnati M; Urbinati C; Presta M
    J Cell Physiol; 1993 Jan; 154(1):152-61. PubMed ID: 8419401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Kinetics of binding of I-125-labeled heparin and its low-molecular-weight fraction CY 222 to the endothelium in vitro].
    Psuja P
    Acta Haematol Pol; 1987; 18(1-2):35-41. PubMed ID: 2829494
    [No Abstract]   [Full Text] [Related]  

  • 18. Tinzaparin sodium: a low-molecular-weight heparin.
    Neely JL; Carlson SS; Lenhart SE
    Am J Health Syst Pharm; 2002 Aug; 59(15):1426-36. PubMed ID: 12166042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route.
    Hiebert LM; Wice SM; Ping T
    Biomed Pharmacother; 2004; 58(6-7):372-80. PubMed ID: 15271419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture.
    Bârzu T; Molho P; Tobelem G; Petitou M; Caen JP
    Nouv Rev Fr Hematol (1978); 1984; 26(4):243-7. PubMed ID: 6473094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.